본문으로 건너뛰기
← 뒤로

How I individualize frontline treatment for chronic-phase CML.

1/5 보강
Blood 📖 저널 OA 34.2% 2025: 19/41 OA 2026: 44/153 OA 2025~2026 2026 Vol.147(4) p. 329-336
Retraction 확인
출처

Leyte-Vidal A, Shah NP

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.8%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Chronic myeloid leukemia (CML) has served as a paradigm for the development of effective initial and next-generation targeted therapies.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Leyte-Vidal A, Shah NP (2026). How I individualize frontline treatment for chronic-phase CML.. Blood, 147(4), 329-336. https://doi.org/10.1182/blood.2024026508
MLA Leyte-Vidal A, et al.. "How I individualize frontline treatment for chronic-phase CML.." Blood, vol. 147, no. 4, 2026, pp. 329-336.
PMID 40239150 ↗

Abstract

Chronic myeloid leukemia (CML) has served as a paradigm for the development of effective initial and next-generation targeted therapies. The availability of 5 effective and generally well-tolerated BCR::ABL1 tyrosine kinase inhibitors for the treatment of newly diagnosed chronic-phase CML offers patients and their treating physicians a welcome luxury of choice. The long-term outlook for patients with newly diagnosed chronic-phase CML is excellent, with expected survival similar to age-matched controls. However, most patients are expected to require lifelong treatment. As a result, important considerations when choosing frontline treatment include not only treatment efficacy but also response durability, tolerability, maximizing quality of life, avoidance of serious and irreversible toxicities, the ease of treatment administration, and, increasingly, the cost of treatment to the patient as well as to society.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반